Survodutide is a dual agonist that activates both GLP‑1 and glucagon receptors[1]. The GLP‑1 component enhances satiety and improves glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation[3]. This dual mechanism is hypothesized to provide additive or synergistic effects on body weight and liver fat beyond GLP‑1 agonism alone[4]. In phase 2 trials, survodutide demonstrated substantial weight loss alongside improvements in liver enzyme markers[1][2].
